ISSN

ISSN 1462-8902
1462-8902 VOLUME
VOLUME 20‚
20‚ NUMBER
NUMBER 3,
3, MARCH
MARCH 2018
2018

DIABETES, OBESITY
AND METABOLISM
A JOURNAL OF PHARMACOLOGY AND THERAPEUTICS

w w w. d o m j o u r n a l . c o m
 Diabetes, Obesity and Metabolism

Editor in Chief News and Views Editor

Professor R. Donnelly, Derby, UK Dr I. Idris, Nottinghamshire, UK
Statistical Advisor
Cassandra Brookes, Leicester, UK

Editorial Office
University of Nottingham, School of Medicine,
Royal Derby Hospital, Uttoxeter Road, Derby, DE22 3DT, UK.
Tel: +44 (0) 1332 724684; Fax: +44 (0) 1332 724697; E-mail: susan.lane@nottingham.ac.uk

S. Arnolds, Neuss, Germany
A. Avogaro, Padova, Italy
C. Bailey, Birmingham, UK
W. Baker, Storrs, USA
D. S. H. Bell, Birmingham, USA
Z. Bloomgarden, New York, USA
J. Buse, Chapel Hill, USA
R. Chilton, Texas, USA
Editorial Board
K. Cusi, Florida, USA
C. Deacon, Copenhagen, Denmark
S. Del Prato, Pisa, Italy
B. Furman, Strathclyde, UK
F. Greenway, Baton Rouge, USA
T. Heise, Neuss, Germany
N. Inagaki, Kyoto, Japan
K. Khunti, Leicester, UK
M-S Lee, Seoul, Korea
T. Lutz, Zurich, Switzerland
J. McGill, St. Louis, USA
L. Meneghini, Texas, USA
W. Waldhäusl, Vienna, Austria
B. Zinman, Toronto, Canada

Editor (Emeritus)
Professor Alan Garber, Houston, USA

Aims and scope

Diabetes, Obesity & Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering
the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports
on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in
any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to
lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic
studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal.
Original research may be published as a main paper or as a research letter.

The journal also invites review articles that are balanced, comprehensive and provide new and/or critical analysis of any aspect
of drug therapy (or non-pharmacological intervention) relevant to patients with diabetes, obesity or metabolic disorders. The
journal will also consider publication of letters to the editor commenting on research already published in the journal, as well
as manuscripts describing new hypotheses or clinical trial protocols.

Copyright and Copying

Copyright © 2018 John Wiley & Sons Ltd. All rights reserved. No part of this publication may be reproduced, stored or trans-
mitted in any form or by any means without the prior permission in writing from the copyright holder. Authorization to copy
items for internal and personal use is granted by the copyright holder for libraries and other users registered with their local
Reproduction Rights Organization (RRO), e.g. Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923,
USA (www.copyright.com), provided the appropriate fee is paid directly to the RRO. This consent does not extend to other
kinds of copying, such as copying for general distribution for advertising or promotional purposes, for creating new collective
works or for resale. Permissions for such reuse can be obtained using the RightsLink “Request Permissions” link on Wiley
Online Library. Special requests should be addressed to: permissions@wiley.com

Disclaimer
The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information con-
tained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither
does the publication of advertisements constitute any endorsement by the Publisher and Editors of the products advertised.